Head and neck cancer survivors patients and late effects related to oncologic treatment: Update of literature

European Review for Medical and Pharmacological Sciences

Volumn 18, Issue 10, 2014, Pages 1473-1481

  Taibi, R ^a,b   Lleshi, A ^a   Barzan, L ^a   Fiorica, F ^c   Leghissa, M ^b   Vaccher, E ^a   De Paoli, P ^a   Franchin, G ^a   Berretta, M ^a,d   Tirelli, U ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b Pordenone General Hospital   (Italy)

^c UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^d Euro Mediterranean Institute of Science and Technology   (Italy)

Author keywords

Cancer; Chemotherapy; Head and neck cancer survivors; Radiation therapy; Survivors

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; CISPLATIN; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; RADIOPHARMACEUTICAL AGENT;

ACUTE TOXICITY; ADVERSE DRUG REACTION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER SURVIVOR; CHEMORADIOTHERAPY; DYSPHAGIA; FREE TISSUE GRAFT; HEAD AND NECK CANCER; HUMAN; INTENSITY MODULATED RADIATION THERAPY; JAW OSTEONECROSIS; MANDIBLE RESECTION; MANDIBULOTOMY; MICROSURGERY; MINIMALLY INVASIVE SURGERY; MOUTH INFECTION; MOUTH PAIN; MOUTH ULCER; ORAL MUCOSITIS; ORAL SURGERY; ORGAN PRESERVATION; OVERALL SURVIVAL; PHOTODYNAMIC THERAPY; POSTOPERATIVE COMPLICATION; PROTON THERAPY; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; ROBOTICS; SALIVATION DISORDER; STEREOTACTIC BODY RADIATION THERAPY; TOOTH INFECTION; TUMOR VOLUME; VOLUMETRIC MODULATED ARC THERAPY; XEROSTOMIA; ADVERSE EFFECTS; HEAD AND NECK NEOPLASMS; STATISTICS AND NUMERICAL DATA; SURVIVOR;

ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; HEAD AND NECK NEOPLASMS; HUMANS; POSTOPERATIVE COMPLICATIONS; SURVIVORS;

EID: 84902209319     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. RIES LAG, HARKINS D, KRAPCHO M (EDS). SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD: National Institutes of Health, 2006; http://seer.cancer.gov/csr/1975-2005.
2. WEINBERGER PM, YU Z, HAFFTY BG, KOWALSKI D, HARIGOPAL M, BRANDSMA J, SASAKI C, JOE J, CAMP RL, RIMM DL, PSYRRI A. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006; 24: 736-747. (Pubitemid 46622040)
3. TIRELLI U, SPINA M, AUGELLO AF, BERRETTA M, ANNUNZIATA MA, BONGIOVANNI M. Is it better to transfer long-term cancer survivors to general practitioners or develop clinics for long-term survivors within the cancer center? J Clin Oncol 2014; 32: 257.
4. TIRELLI U, ANNUNZIATA MA, SPINA M, DAL MASO L, BERRETTA M. Long-term cancer survivorship: a new challenge that requires a new follow-up approach. Eur Rev Med Pharmacol Sci 2011; 15: 725-726.
5. SIMONELLI C, ANNUNZIATA MA, CHIMIENTI E, BERRETTA M, TIRELLI U. Cancer survivorship: a challenge for the European oncologists. Ann Oncol 2008; 19: 1216-1217. (Pubitemid 351911948)
6. SIMONELLI C, BERRETTA M, TIRELLI U, ANNUNZIATA MA. Clinical management of long-term cancer survivors. J Clin Oncol 2008: 26: 161-162.
7. Hewitt M, Greenfield S, Stovall E (eds) From Cancer Patient to Cancer Survivor: Lost in Transition. The National Academies Press, Washington DC, 2006.
8. SMITH GL, SMITH BD, GIORDANO SH, SHIH YC, WOODWARD WA, STROM EA, PERKINS GH, TEREFFE W, YU TK, BUCHHOLZ TA. Risk of hypothyroidism in older breast cancer patients treated with radiation. Cancer 2008; 112: 1371-1379. (Pubitemid 351429753)
9. GIACALONE A, QUINTADAMO D, ZANET E, BERRETTA M, SPINA M, TIRELLI U. Cancer-related fatigue in the elderly. Support Care Cancer 2013: 21: 2899-2911.
10. GIACALONE A, BERRETTA M, SPINA M, TIRELLI U. Is longterm fatigue in patients with cancer an infrequent symptom? J Clin Oncol 2012; 30: 4175-4176.
11. GIACALONE A, SPINA M, BERRETTA M, TIRELLI U. Two types of fatigue in cancer patients. Br J Cancer 2012; 106: 424.
12. HEFLIN LH, MEYEROWITZ BE, HALL P, LICHTENSTEIN P, JOHANSSON B, PEDERSEN NL, GATZ M. Cancer as a risk factor for long-term cognitive deficits and dementia. J Natl Cancer Inst 2005; 97: 854-856. (Pubitemid 40909128)
13. COHAN DM, POPAT S, KAPLAN SE, RIGUAL N, LOREE T, HICKS WL JR. Oropharyngeal cancer: current understanding and management. Curr Opin Otolaryngol Head Neck Surg 2009; 17: 88-94.
14. TALAMINI R, BOSETTI C, LA VECCHIA C, DAL MASO L, LEVI F, BIDOLI E, NEGRI E, PASCHE C, VACCARELLA S, BARZAN L, FRANCESCHI S. Combined effect of tobacco and alcohol on laryngeal cancer risk: a casecontrol study. Cancer Causes Control 2002; 13: 957-964. (Pubitemid 36169479)
15. JEMAL A, SIEGEL R, XU J, WARD E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
16. National Cancer Institute. Available at: http://www.cancer.gov/. Accessed December 30, 2009.
17. DENIS F, GARAUD P, BARDET E, ALFONSI M, SIRE C, GERMAIN T, BERGEROT P, RHEIN B, TORTOCHAUX J, CALAIS G. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004; 22: 69-76. (Pubitemid 41095116)
18. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991; 324: 1685-1690.
19. FORASTIERE AA, GOEPFERT H, MAOR M, PAJAK TF, WEBER R, MORRISON W, GLISSON B, TROTTI A, RIDGE JA, CHAO C, PETERS G, LEE DJ, LEAF A, ENSLEY J, COOPER J. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091-2098. (Pubitemid 37464533)
20. LEFEBVRE JL, CHEVALIER D, LUBOINSKI B, KIRKPATRICK A, COLLETTE L, SAHMOUD T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996; 88: 890-899. (Pubitemid 26230640)
21. ADELSTEIN DJ, SAXTON JP, RYBICKI LA, ESCLAMADO RM, WOOD BG, STROME M, LAVERTU P, LORENZ RR, CARROLL MA. Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. J Clin Oncol 2006; 24: 1064-1071. (Pubitemid 46638803)
22. PIGNON JP, BOURHIS J, DOMENGE C, DESIGNÉ L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 2000; 355: 949-955. (Pubitemid 30148259)
23. SHAH JP, GIL Z. Current concepts in management of oral cancer-surgery. Oral Oncol 2009; 45: 394-401.
24. LINSEN SS, MARTINI M, STARK H. Long-term results of endosteal implants following radical oral cancer surgery with and without adjuvant radiation therapy. Clin Implant Dent Relat Res 2012; 14: 250-258.
25. HARTL DM, FERLITO A, SILVER CE, TAKES RP, STOECKLI SJ, SUÁREZ C, RODRIGO JP, SESTERHENN AM, SNYDERMAN CH, TERRIS DJ, GENDEN EM, RINALDO A. Minimally invasive techniques for head and neck malignancies: current indications, outcomes and future directions. Eur Arch Otorhinolaryngol 2011; 268: 1249-1257.
26. GENDEN EM, KOTZ T, TONG CC, SMITH C, SIKORA AG, TENG MS, PACKER SH, LAWSON WL, KAO J.Transoral robotic resection and reconstruction for head and neck cancer. Laryngoscope 2011; 121: 1668-1674.
27. O'MALLEY BW JR, WEINSTEIN GS, SNYDER W, HOCKSTEIN NG. Transoral robotic surgery (TORS) for base of tongue neoplasms. Laryngoscope 2006; 116: 1465-1472. (Pubitemid 44181466)
28. WEINSTEIN GS, O'MALLEY BW JR, SNYDER W, SHERMAN E, QUON H. Transoral robotic surgery: radical tonsillectomy. Arch Otolaryngol Head Neck Surg 2007; 133: 1220-1226. (Pubitemid 350294250)
29. MURPHY BA. Clinical and economic consequences of mucositis induced by chemotherapy and/or radiation therapy. J Support Oncol 2007; 5(9 Suppl 4): 13-21. (Pubitemid 350041363)
30. BENSINGER W, SCHUBERT M, ANG KK, BRIZEL D, BROWN E, EILERS JG, ELTING L, MITTAL BB, SCHATTNER MA, SPIELBERGER R, TREISTER NS, TROTTI AM 3RD. NCCN Task Force Report: prevention and management of mucositis in cancer care. J Natl Compr Canc Netw 2008; 6 (Suppl 1): S1-S21; quiz S22-S24. (Pubitemid 351160494)
31. BOERS-DOETS CB, EPSTEIN JB, RABER-DUR-LACHER JE, OUWERKERK J, LOGAN RM, BRAKENHOFF JA, LACOUTURE ME, GELDERBLOM H. Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist 2012; 17: 135-144.
32. DE OLIVEIRA MA, MARTINS E, MARTINS F, WANG Q, SONIS S, DEMETRI G, GEORGE S, BUTRYNSKI J, TREISTER NS. Clinical presentation and management of mTOR inhibitor-associated stomatitis. Oral Oncol 2011; 47: 998-1003.
33. MULTINATIONAL ASSOCIATION OF SUPPORTIVE CARE IN CANCER (MASCC). Mucositis Guidelines. mascc.org. Accessed July 22, 2012.
34. KEEFE DM, SCHUBERT MM, ELTING LS, SONIS ST, EPSTEIN JB, RABER-DURLACHER JE, MIGLIORATI CA, MCGUIRE DB, HUTCHINS RD, PETERSON DE; MUCOSITIS STUDY SECTION OF THE MULTINATIONAL ASSOCIATION OF SUPPORTIVE CARE IN CANCER AND THE INTERNATIONAL SOCIETY FOR ORAL ONCOLOGy. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007; 109: 820-831. (Pubitemid 46335677)
35. PRESS MF, LENZ HJ. EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs 2007; 67: 2045-2075. (Pubitemid 47524565)
36. TRIANO LR, DESHPANDE H, GETTINGER SN. Management of patients with advanced non-small cell lung cancer: current and emerging options. Drugs 2010; 70: 167-179.
37. CHANG JE, KAHL BS. Current status of targeted therapies for mantle cell lymphoma. Drugs 2011; 71: 2307-2326.
38. WATTERS AL, EPSTEIN JB, AGULNIK M. Oral complications of targeted cancer thera- pies: a narrative literature review. Oral Oncol 2011; 47: 441-448.
39. HORIOT JC, LE FUR R, NGUYEN T, CHENAL C, SCHRAUB S, ALFONSI S, GARDANI G, VAN DEN BOGAERT W, DANCZAK S, BOLLA M, et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 1992; 25: 231-241. (Pubitemid 23000765)
40. PARSONS JT, MENDENHALL WM, STRINGER SP, CASSISI NJ, MILLION RR. Twice-a-day radio- therapy for squamous cell carcinoma of the head and neck: the University of Florida experience. Head Neck 1993; 15: 87-96. (Pubitemid 23066885)
41. GARDEN AS, MORRISON WH, ANG KK, PETERS LJ. Hyperfractionated radiation in the treatment of squamous cell carcinomas of the head and neck: a comparison of two fractionation schedules. Int J Radiat Oncol Biol Phys 1995; 31: 493-502.
42. FU KK, PAJAK TF, TROTTI A, JONES CU, SPENCER SA, PHILLIPS TL, GARDEN AS, RIDGE JA, COOPER JS, ANG KK. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000; 48: 7-16. (Pubitemid 30488207)
43. ALTMAN MB, CHMURA SJ, DEASY JO, ROESKE JC. Optimization of the temporal pattern of radiation: an IMRT based study. Int J Radiat Oncol Biol Phys 2006; 66: 898-905. (Pubitemid 44436720)
44. YANG J, FOWLER JF, LAMOND JP, LANCIANO R, FENG J, BRADY LW. Red shell: defining a high-risk zone of normal tissue damage in stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2010; 77: 903-909.
45. KRAYENBUEHL J, DAVIS JB, CIERNIK IF. Dynamic intensity- modulated non-coplanar arc radiotherapy (INCA) for head and neck cancer. Radiother Oncol 2006; 81: 151-157. (Pubitemid 44708369)
46. KORREMAN S, MEDIN J, KJAER-KRISTOFFERSEN F. Dosimetric verification of RapidArc treatment delivery. Acta Oncol 2009; 48: 185-191.
47. VANETTI E, CLIVIO A, NICOLINI G, FOGLIATA A, GHOSHLASKAR S, AGARWAL JP, UPRETI RR, BUDRUKKAR A, MURTHY V, DESHPANDE DD, SHRIVASTAVA SK, DINSHAW KA, COZZI L. Volumetric modulated arc radiotherapy for carcinomas of the oropharynx, hypopharynx and larynx: a treatment planning comparison with fixed field IMRT. Radiother Oncol 2009; 92: 111-117.
48. DOORNAERT P, VERBAKEL WF, BIEKER M, SLOTMAN BJ, SENAN S. RapidArc planning and delivery in patients with locally advanced head-and-neck cancer undergoing chemo- radiotherapy. Int J Radiat Oncol Biol Phys 2011; 79: 429-435.
49. VAN VULPEN M, FIELD C, RAAIJMAKERS CP, PARLIAMENT MB, TERHAARD CH, MACKENZIE MA, SCRIMGER R, LAGENDIJK JJ, FALLONE BG. Comparing step-and-shoot IMRT with dynamic helical tomotherapy IMRT plans for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2005; 62: 1535-1539. (Pubitemid 40982080)
50. FIORINO C, DELLOCA I, PIERELLI A, BROGGI S, DE MARTIN E, DI MUZIO N, LONGOBARDI B, FAZIO F, CALANDRINO R. Significant improvement in normal tissue sparing and target coverage for head and neck cancer by means of helical tomotherapy. Radiother Oncol 2006; 78: 276-282.
51. SHENG K, MOLLOY JA, LARNER JM, READ PW. A dosimetric comparison of non-coplanar IMRT versus helical tomotherapy for nasal cavity and paranasal sinus cancer. Radiother Oncol 2007; 82: 174-178. (Pubitemid 46275139)
52. CHEN AM, JENNELLE RL, SREERAMAN R, YANG CC, LIU T, VIJAYAKUMAR S, PURDY JA. Initial clinical experience with helical tomotherapy for head and neck cancer. Head Neck 2009; 31: 1571-1578.
53. KODAIRA T, TOMITA N, TACHIBANA H, NAKAMURA T, NAKAHARA R, INOKUCHI H, FUWA N. Aichi cancer center initial experience of intensity modulated radiation therapy for nasopharyngeal cancer using helical tomotherapy. Int J Radiat Oncol Biol Phys 2009; 73: 1129-1134.
54. FARRAG A, VOORDECKERS M, TOURNEL K, DE CONINCK P, STORME G. Pattern of failure after helical tomotherapy in head and neck cancer. Strahlenther Onkol 2010; 186: 511-516.
55. MOON SH, JUNG YS, RYU JS, CHOI SW, PARK JY, YUN T, LEE SH, CHO KH. Outcomes of postoperative simultaneous modulated accelerated radiotherapy for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2011; 81: 140-149.
56. MURTHY V, MASTER Z, GUPTA T, GHOSH-LASKAR S, BUDRUKKAR A, PHURAILATPAM R, AGARWAL J. Helical tomotherapy for head and neck squamous cell carcinoma: dosimetric comparison with linear accelerator- based step-and-shoot IMRT. J Cancer Res Ther 2010; 6: 194-198.
57. VOORDECKERS M, EVERAERT H, TOURNEL K, VERELLEN D, BARON I, VAN ESCH G, VANHOVE C, STORME G. Longitudinal assessment of parotid function in patients receiving tomotherapy for head-and-neck cancer. Strahlenther Onkol 2008; 184: 400-405.
58. HERON DE, FERRIS RL, KARAMOUZIS M, ANDRADE RS, DEEB EL, BURTON S, GOODING WE, BRANSTETTER BF, MOUNTZ JM, JOHNSON JT, ARGIRIS A, GRANDIS JR, LAI SY. Stereotactic body radiotherapy for recur- rent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial. Int J RadiatOncol Biol Phys 2009; 75: 1493-1500.
59. ROH KW, JANG JS, KIM MS, SUN DI, KIM BS, JUNG SL, KANG JH, YOO EJ, YOON SC, JANG HS, CHUNG SM, KIM YS. Fractionated stereotactic radiotherapy as re-irradiation for locally recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 2009; 74: 1348-1355.
60. RWIGEMA JC, HERON DE, FERRIS RL, GIBSON M, QUINN A, YANG Y, OZHASOGLU C, BURTON S. Fractionated stereotactic body radiation therapy in the treatment of previously-irradiated recurrent head and neck carcinoma: updated report of the University of Pittsburgh experience. Am J Clin Oncol 2010; 33: 286-293.
61. SIDDIQUI F, PATEL M, KHAN M, MCLEAN S, DRAGOVIC J, JIN JY, MOVSAS B, RYU S. Stereo- tactic body radiation therapy for primary, recurrent, and metastatic tumors in the head-and-neck region. Int J Radiat Oncol Biol Phys 2009; 74: 1047-1053.
62. TRUONG MT, GRILLONE G, TSCHOE C, CHIN L, KACHNIC LA, JALISI S. Emerging applications of stereotactic radiotherapy in head and neck cancer. Neurosurg Focus 2009; 27: E11.
63. ZHANG X, LI Y, PAN X, XIAOQIANG L, MOHAN R, KOMAKI R, COX JD, CHANG JY. Intensity- modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study. Int J Radiat Oncol Biol Phys 2010; 77: 357-366.
64. ZHANG X, PENAGARICANO J, MOROS EG, CORRY PM, YAN Y, RATANATHARATHORN V. Dosimetric comparison of helical tomotherapy and linac-IMRT treatment plans for head and neck cancer patients. Med Dosim 2010; 35: 264-268.
65. KAWAGUCHI K, SATO K, HORIE A, IKETANI S, YAMADA H, NAKATANI Y, SATO J, HAMADA Y. Stereotactic radiosurgery may contribute to overall survival for patients with recurrent head and neck carcinoma. Radiat Oncol 2010; 5: 51.
66. CENGIZ M, ÖZYI IT G, YAZICI G, DO AN A, YILDIZ F, ZORLU F, GÜRKAYNAK M, GULLU IH, HOSAL S, AKYOL F. Salvage re-irradiation with stereotactic body radiotherapy for locally recurrent head-and-neck tumors. Int J Radiat Oncol Biol Phys 2011; 81: 104-109.
67. BEGG AC, STEWART FA, VENS C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 2011; 11: 239-253.
68. BONNER JA, HARARI PM, GIRALT J, AZARNIA N, SHIN DM, COHEN RB, JONES CU, SUR R, RABEN D, JASSEM J, OVE R, KIES MS, BASELGA J, YOUSSOUFIAN H, AMELLAL N, ROWINSKY EK, ANG KK. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578. (Pubitemid 43209104)
69. ANG KK, ZHANG QE, ROSEHTHAL II. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation and cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinoma. J Clin Oncol 2011; 29 (Suppl.) Abstr. 5500.
70. LANGENDIJK JA, DOORNAERT P, VERDONCK-DE LEEUW IM, LEEMANS CR, AARONSON NK, SLOTMAN BJ. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol 2008; 26: 3770-3776.
71. KOTZ T, COSTELLO R, LI Y, POSNER MR. Swallowing dysfunction after chemoradiation for advanced squamous cell carcinoma of the head and neck. Head Neck 2004; 26: 365-372. (Pubitemid 38436676)
72. EISBRUCH A, T LYDEN CR BRADFORD DAWSON LA, HAXER MJ, MILLER AE, TEKNOS TN, CHEPEHA DB, HOGIKYAN ND, TERRELL JE, WOLF GT. Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head-andneck cancer. Int J Radiat Oncol Biol Phys 2002; 53: 23-28. (Pubitemid 34465803)
73. LOGEMANN JA, PAULOSKI BR, RADEMAKER AW, COLANGELO LA. Super-supraglottic swallow in irradiated head and neck cancer patients. Head Neck 1997; 19: 535-540. (Pubitemid 27349673)
74. LAZARUS CL, LOGEMANN JA, SONG CW, RADEMAKER AW, KAHRILAS PJ. Effects of voluntary maneuvers on tongue base function for swallowing. Folia Phoniatr Logop 2002; 54: 171-176. (Pubitemid 34920709)
75. KOT T, FEDERMAN AD, KAO J, MILMAN L, PACKER S, LOPEZ-PRIETO C, FORSYTHE K, GENDEN EM. Prophylactic swallowing exercises in patients with head and neck cancer undergoing chemoradiation. Arch Otolaryngol Head Neck Surg 2012; 138: 376-382.
76. HADERLEIN M, SEMRAU S, OTT O, SPEER S, BOHR C, FIETKAU R. Dose-dependent deterioration of swallowing function after induction chemotherapy and definitive chemoradiotherapy for laryngopharyngeal cancer. Strahlenther Onkol 2014; 190: 192-198.
77. EISBRUCH A, KIM HM, TERRELL JE, MARSH LH, DAWSON LA, SHIP JA. Xerostomia and its predictors following parotid sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 50:695-704. (Pubitemid 32515326)
78. CHAO, KS, N MAJHAIL, CJ HUANG, SIMPSON JR, PEREZ CA, HAUGHEY B, SPECTOR G. Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. Radiother Oncol 2001; 61: 275-280. (Pubitemid 33127232)
79. COLASANTO JM, PRASAD P, NASH MA DECKER RH, WILSON LD. Nutritional supporto f patients undergoing radiation therapy for head and neck cancer. Oncology (Williston Park) 2005; 19: 371-379. (Pubitemid 350054579)
80. SCHNOLL RA, ZHANG B, RUE M, KROOK JE, SPEARS WT, MARCUS AC, ENGSTROM PF. Brief physician-initiated quit-smoking strategies for clinical oncology settings: a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2003; 21: 355-365. (Pubitemid 46606166)
81. GRITZ ER, CARR CR, RAPKIN D, ABEMAYOR E, CHANG LJC, WONG W-K, BELIN TR, CALCATERRA T, ROBBINS KT, CHONKICH G, BEUMER J, WARD PH. Predictors of long-term smoking cessation in head and neck cancer patients. Cancer Epidemiol Biomarkers Prev 1993; 2: 261-270.
82. PATRICK D, ERICKSON P. Health status and health policy: quality of life in health care evaluation and resource allocation. New York: Oxford University Press, 1993.